| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
108,030,000 |
| Market
Cap: |
54.46(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4901 - $1.4 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Selecta Biosciences is a clinical-stage biopharmaceutical company. Co.'s ImmTOR® platform encapsulates rapamycin, also known as sirolimus, a Food and Drug Administration approved immunomodulator, in biodegradable nanoparticles ImmTOR is designed to induce antigen-specific immune tolerance. By combining ImmTOR with antigens of interest, Co.'s immune tolerance platform restores self-tolerance to auto-antigens in autoimmune diseases, amplify the ability of biologics (including gene therapies) and mitigate the formation of anti-drug antibodies against biologic drugs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,222,516 |
1,223,316 |
1,223,316 |
1,403,316 |
| Total Buy Value |
$688,511 |
$689,063 |
$689,063 |
$877,582 |
| Total People Bought |
1 |
1 |
1 |
3 |
| Total Buy Transactions |
12 |
13 |
13 |
15 |
| Total Shares Sold |
0 |
0 |
3,637 |
15,619 |
| Total Sell Value |
$0 |
$0 |
$3,855 |
$23,149 |
| Total People Sold |
0 |
0 |
2 |
2 |
| Total Sell Transactions |
0 |
0 |
2 |
5 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Johnston Lloyd P. |
COO and SVP, R&D |
• – – |
2017-06-15 |
4/A |
AS |
$17.04 |
$179,141 |
D/D |
(10,512) |
1,606 |
|
- |
|
| Johnston Lloyd P. |
COO and SVP, R&D |
• – – |
2017-06-15 |
4/A |
OE |
$0.47 |
$4,941 |
D/D |
10,512 |
12,118 |
|
- |
|
| Johnston Lloyd P. |
COO and SVP, R*D |
• – • |
2017-06-15 |
4 |
AS |
$17.00 |
$348,640 |
D/D |
(20,512) |
1,606 |
|
- |
|
| Johnston Lloyd P. |
COO and SVP, R*D |
• – • |
2017-06-15 |
4 |
OE |
$0.47 |
$9,641 |
D/D |
20,512 |
22,118 |
|
- |
|
| Springer Timothy A |
Director |
– • – |
2017-06-01 |
4 |
B |
$13.75 |
$7,123 |
D/D |
518 |
16,622 |
2.39 |
- |
|
| Springer Timothy A |
Director |
– • – |
2017-05-18 |
4 |
B |
$14.00 |
$68,040 |
D/D |
4,860 |
16,104 |
2.39 |
- |
|
| Springer Timothy A |
Director |
– • – |
2017-05-17 |
4 |
B |
$14.01 |
$157,483 |
D/D |
11,244 |
11,244 |
2.39 |
- |
|
| Kania Edwin M Jr |
Director |
– • – |
2017-05-16 |
4 |
S |
$14.00 |
$3,735,130 |
I/I |
(266,795) |
560,067 |
|
- |
|
| Johnston Lloyd P. |
COO AND SVP, R&D |
• – – |
2017-04-17 |
4 |
AS |
$13.95 |
$184,210 |
D/D |
(13,205) |
1,606 |
|
- |
|
| Johnston Lloyd P. |
COO AND SVP, R&D |
• – – |
2017-04-17 |
4 |
OE |
$0.39 |
$5,150 |
D/D |
13,205 |
14,811 |
|
- |
|
| Barabe Timothy C |
Director |
– • – |
2017-03-27 |
4 |
OE |
$11.00 |
$27,412 |
D/D |
2,492 |
2,492 |
|
- |
|
| Farokhzad Omid |
Director |
– • – |
2017-03-23 |
4 |
OE |
$3.44 |
$235,108 |
D/D |
60,000 |
188,004 |
|
- |
|
| Johnston Lloyd P. |
COO AND SVP, R&D |
• – – |
2017-01-23 |
4 |
AS |
$13.95 |
$210,106 |
D/D |
(15,000) |
1,606 |
|
- |
|
| Johnston Lloyd P. |
COO AND SVP, R&D |
• – – |
2017-01-23 |
4 |
OE |
$0.39 |
$5,850 |
D/D |
15,000 |
16,606 |
|
- |
|
| Kishimoto Takashi Kei |
Chief Scientific Officer |
• – – |
2016-12-28 |
4 |
S |
$17.55 |
$175,500 |
D/D |
(10,000) |
0 |
|
- |
|
| Kishimoto Takashi Kei |
Chief Scientific Officer |
• – – |
2016-12-28 |
4 |
OE |
$2.77 |
$27,700 |
D/D |
10,000 |
10,000 |
|
- |
|
| Abraham David |
CCO, Gen.Counsel, Corp.Sec. |
• – – |
2016-12-21 |
4 |
S |
$18.00 |
$267,192 |
D/D |
(14,844) |
0 |
|
- |
|
| Abraham David |
CCO, Gen.Counsel, Corp.Sec. |
• – – |
2016-12-21 |
4 |
OE |
$0.47 |
$5,772 |
D/D |
12,280 |
14,844 |
|
- |
|
| Keller Peter |
Chief Business Officer |
• – – |
2016-12-19 |
4 |
S |
$18.58 |
$87,753 |
D/D |
(4,723) |
405 |
|
- |
|
| Nanodimension Limited Partnership |
10% Owner |
– – • |
2016-06-27 |
4 |
B |
$14.00 |
$5,390,000 |
I/I |
385,000 |
1,045,957 |
1.5 |
- |
|
| Nanodimension Limited Partnership |
10% Owner |
– – • |
2016-06-27 |
4 |
A |
$0.00 |
$0 |
I/I |
637,790 |
660,957 |
|
- |
|
| Osage Partners, Llc |
10% Owner |
– – • |
2016-06-27 |
4 |
B |
$14.00 |
$4,900,000 |
I/I |
350,000 |
862,543 |
1.5 |
- |
|
| Osage Partners, Llc |
10% Owner |
– – • |
2016-06-27 |
4 |
A |
$0.00 |
$0 |
I/I |
441,628 |
512,543 |
|
- |
|
| Springer Timothy A |
Director |
– • – |
2016-06-27 |
4 |
B |
$14.00 |
$9,940,000 |
I/I |
710,000 |
1,237,028 |
2.1 |
- |
|
| Springer Timothy A |
Director |
– • – |
2016-06-27 |
4 |
A |
$0.00 |
$0 |
I/I |
931,889 |
445,576 |
|
- |
|
258 Records found
|
|
Page 9 of 11 |
|
|
